Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib + Immuno-chemotherapy in Untreated CLL
NCT07624799Phase 2Not yet recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Sep 2026
- Primary completion
- Sep 2028
01
Overview
A Phase 2 trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), sponsored by French Innovative Leukemia Organisation. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07624799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624799.